he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
下一页:一文掌握抑郁症用药宝典
- 2022-05-05新冠再现3个新变种!传染性又韶山?
- 2022-04-252013年国际抗癫痫执行委员会抗癫痫药使用指南
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 月经性癫痫患者妊娠期癫痫控制更好
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫治疗障碍仍难以克服
- 2013国际抗癫痫联合会抗癫痫药用指南
- 上海率先探索异地就医门诊费直接结算
- 抗癫痫药物预防新发癫痫:任重而道远
- 2016AAN:神经专家发表了有前途的专业见解
- 癫痫需要如何诊断?
- 癫痫猝死:凶手是谁?
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 羊角病能生孩子吗?
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 心率多少正常 如何保持正常心率不变
- UCB的Vimpat癫痫新适应症在美国获批
- 延迟性癫痫患者中风预后较差
- 不注意这些问题,吃多少药都没用!
- 北京哪家癫痫医院排名好,成本低
- FDA警告怀孕期间使用丙戊酸钠药物
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 控制癫痫患者再次抽搐,不包括可选药物?
- 预测癫痫患者再入院风险
- 罕见病例:自发性颞极性扩张伴癫痫发作
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 20首款慢性肾脏病治疗药物Forxiga获得NICE推荐
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 最大限度癫痫病治疗的日常习惯
- 原发癫痫病能康复吗
- 为什么癫痫病久治不愈
- 怎么治继发性羊癫疯 羊癫疯疗法方法有什么
- 怎么用生物学的方法治疗癫痫病
- 全面性癫痫的先兆学术研究
- Circ Ep:腺苷实验可鉴别复发AF消融术时的隐匿传导静脉
- 癫痫病长时间发作怎么办
- 治疗癫痫病小发烧药物
- 治疗法癫痫病有特效药
- 羊癫疯治疗方法有有哪些 五个治疗方法有效果好
- 老人得了癫痫病有什么症状
- 卫材在法国推出一代抗癫痫药Fycompa